.

New Growth Funding Mecuris GmbH

Munich, Germany, January 13th, 2020 – German med-tech company Mecuris GmbH has successfully concluded a new funding round amounting to 3.6 million euros. In addition to the seed investors Bayern Kapital and High-Tech Gründerfonds (HTGF), the international investment company Mulcan, life science venture capital investor Vesalius Biocapital, and Sana Kliniken AG, one of the top five hospital chains in Germany, are once again also on board.

3D-Druck in der Medizintechnik

München, 13.12.2019 – Die Bundesregierung sieht großes Potenzial im Einsatz von 3D-Druck in der Medizintechnik – insbesondere für patientenindividuelle Sonderanfertigungen von Prothesen oder Orthesen. Das geht aus der Antwort auf die kleine Anfrage der FDP-Bundestagsfraktion „Prothesen aus dem 3D-Drucker für Menschen mit Behinderungen" hervor.

Forendo Pharma Deal with Novartis

Turku, Finland, December 11th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces signing of a License and Collaboration Agreement with Novartis. The joint research collaboration is aimed at the identification of novel drugs for the treatment of chronic liver diseases. Novartis receives a worldwide exclusive license to drug candidates generated under the collaboration.

Tonic App raises 3.5 million euros

August 27th 2019: Tonic App, the startup that developed the favourite mobile application of more than 12,000 medical doctors, has raised 3.5 million euros in a round co-led by Vesalius Biocapital Partners (Luxembourg) and Armilar Venture Partners (Portugal), joining Portugal Ventures and TheVentureCity.

Mecuris GmbH: Best MedTech Startup

Mecuris GmbH, a commercial-stage Munich-based medical technology startup focusing on the digitalization of prosthetics and orthotics, has been listed as one of the Best European MedTech Startups by Valuer. Vesalius Biocapital supports the innovative Mecuris approach since January 2019.

Forendo: Phase 1b Proof

Turku, Finland, August 20th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis program with the aim to demonstrate Proof of Mechanism.

Sunstone Life Science joins Syndicate

Turku, Finland, July 19th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces that Sunstone Life Science Ventures has made a €5 million investment in Forendo.

Investment in DEARhealth

AMSTERDAM 18 July 2019 - DEARhealth, a health tech spin-out from the University of California, Los Angeles (UCLA), today announced a first closing of its Series A round with Philips Health Technology Ventures, Vesalius Biocapital III and Health Innovations. DEARhealth offers Artificial Intelligence (AI)-powered health pathways for chronic care.

Schneider-Littfeld in Advisory Board

Munich, 04.07.2019 - The Munich based medical technology startup Mecuris GmbH won industry expert Johannes Schneider Littfeld as Chairman of the Advisory Board. The company Mecuris offers a digital workshop for the creation and individualisation of prostheses and orthoses.

Final Close of EUR 120 million Fund

Luxembourg-Strassen, June 25, 2019 – Vesalius Biocapital III ('Vesalius'), the specialist life sciences venture capital investor, announces the final close of the VBC III fund securing EUR 120 million of equity commitments.

.

xxnoxx_zaehler